Shares of medical technology company Enovis Corporation (NYSE: ENOV) surged 6.72% in the pre-market session on Wednesday, following the company's better-than-expected fourth quarter 2024 earnings report and upbeat guidance for 2025.

For the fourth quarter, Enovis reported adjusted earnings per share of $0.98, beating the consensus estimate of $0.92. Revenue for the quarter came in at $561 million, exceeding analysts' expectations of $555.1 million.

Looking ahead to 2025, Enovis provided an optimistic outlook, forecasting revenue in the range of $2.19 billion to $2.22 billion, which includes organic growth of 6% to 6.5%. This revenue guidance is largely in line with the consensus estimate of $2.22 billion. The company also expects adjusted earnings per share to be between $3.10 and $3.25, higher than the consensus estimate of $3.16.

In a separate announcement, Enovis revealed that its Chief Executive Officer, Matt Trerotola, has informed the Board of Directors of his intention to retire. The company has initiated a succession planning process and is actively working with an executive search firm to identify a growth-oriented MedTech leader to serve as the next CEO. Trerotola will continue to serve as an employee and Executive Advisor for one year after his successor is appointed to facilitate a smooth transition.